@article{TCR4536,
author = {Nicolas Goossens and Shigeki Nakagawa and Xiaochen Sun and Yujin Hoshida},
title = {Cancer biomarker discovery and validation},
journal = {Translational Cancer Research},
volume = {4},
number = {3},
year = {2015},
keywords = {},
abstract = {With the emergence of genomic profiling technologies and selective molecular targeted therapies, biomarkers play an increasingly important role in the clinical management of cancer patients. Single gene/protein or multi-gene “signature”-based assays have been introduced to measure specific molecular pathway deregulations that guide therapeutic decision-making as predictive biomarkers. Genomebased prognostic biomarkers are also available for several cancer types for potential incorporation into clinical prognostic staging systems or practice guidelines. However, there is still a large gap between initial biomarker discovery studies and their clinical translation due to the challenges in the process of cancer biomarker development. In this review we summarize the steps of biomarker development, highlight key issues in successful validation and implementation, and overview representative examples in the oncology field. We also discuss regulatory issues and future perspectives in the era of big data analysis and precision medicine.},
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/4536}
}